The multitarget FAAH inhibitor/D3 partial agonist ARN15381 decreases nicotine self-administration in male rats

Veronica Lunerti, Hongwu Li, Federica Benvenuti, Qianwei Shen, Ana Domi, Laura Soverchia, Rita Maria Concetta Di Martino, Giovanni Bottegoni, Carolina L Haass-Koffler, Nazzareno Cannella. Eur J Pharmacol. 2022 Aug 5:928:175088.

Laboratory studyOther animalsWith ARN15381 (a FAAH inhibitor and D3 partial agonist), URB597 and CJB090; palmitoylethanolamide itself was not given

This study tested palmitoylethanolamide together with ARN15381 (a FAAH inhibitor and D3 partial agonist), URB597 and CJB090; palmitoylethanolamide itself was not given. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design

Laboratory study

Subjects

Male rats trained to self-administer nicotine; numbers not stated in the abstract

Dose used in the study

Not stated in the abstract

Duration

Not stated in the abstract

What was measured

Nicotine self-administration after pretreatment with ARN15381, the FAAH inhibitor URB597 or the D3 partial agonist CJB090.

What the authors reported

ARN15381 dose-dependently reduced self-administration of a high nicotine dose but not a lower dose. URB597 and CJB090 given alone did not change nicotine self-administration at either dose.

Limits of this study

A rat study; it cannot show effect in people. Palmitoylethanolamide is mentioned only as one of the lipids broken down by FAAH; PEA was not given. Funding and conflicts not stated in the abstract.

Source

PubMed 35690082 · doi:10.1016/j.ejphar.2022.175088

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.